NCT06337318 2026-03-18
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
National Cancer Institute (NCI)
Phase 3 Recruiting
Clinical Trials
3 trialsNCT03267433 2026-03-02
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05289687 2026-03-02
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
Phase 2 Recruiting